These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20425407)

  • 41. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
    Reinis M
    Curr Opin Mol Ther; 2007 Jun; 9(3):291-8. PubMed ID: 17608028
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma.
    Ruffini PA; Di Nicola M; Carlo-Stella C; Siena S; Gianni AM
    Curr Gene Ther; 2005 Oct; 5(5):511-21. PubMed ID: 16250891
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
    Timmerman JM; Vose JM; Czerwinski DK; Weng WK; Ingolia D; Mayo M; Denney DW; Levy R
    Leuk Lymphoma; 2009 Jan; 50(1):37-46. PubMed ID: 19125383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.
    Villanueva H; de Cerio AL; Inoges S; Pastor F; Soldevilla MM; Bendandi M
    Expert Rev Vaccines; 2011 Dec; 10(12):1661-9. PubMed ID: 22085168
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-idiotype vaccines for human follicular lymphoma.
    Bendandi M
    Leukemia; 2000 Aug; 14(8):1333-9. PubMed ID: 10942225
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model.
    Roehnisch T; Then C; Nagel W; Blumenthal C; Braciak T; Donzeau M; Böhm T; Bourquin C; Oduncu F
    J Transl Med; 2013 Oct; 11():267. PubMed ID: 24152874
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma.
    Timmerman JM
    Adv Pharmacol; 2004; 51():271-93. PubMed ID: 15464914
    [No Abstract]   [Full Text] [Related]  

  • 48. Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.
    Carlring J; Szabo MJ; Dickinson R; De Leenheer E; Heath AW
    Blood; 2012 Mar; 119(9):2056-65. PubMed ID: 22234700
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor vaccination strategies combined with autologous peripheral stem cell transplantation.
    Kwak LW
    Ann Oncol; 1998; 9 Suppl 1():S41-6. PubMed ID: 9581240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic vaccine for lymphoma.
    Lee ST; Neelapu SS; Kwak LW
    Yonsei Med J; 2007 Feb; 48(1):1-10. PubMed ID: 17326239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.
    Rhee Fv
    Clin Cancer Res; 2007 Mar; 13(5):1353-5. PubMed ID: 17332275
    [No Abstract]   [Full Text] [Related]  

  • 52. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):67. PubMed ID: 16227966
    [No Abstract]   [Full Text] [Related]  

  • 53. Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine.
    Ansell SM; Suman VJ
    J Clin Oncol; 2011 Jul; 29(20):2748-9. PubMed ID: 21632499
    [No Abstract]   [Full Text] [Related]  

  • 54. The development of a bicistronic plasmid DNA vaccine for B-cell lymphoma.
    Singh G; Parker S; Hobart P
    Vaccine; 2002 Jan; 20(9-10):1400-11. PubMed ID: 11818159
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma?
    Schuster SJ; Neelapu SS; Santos CF; Popa-McKiver MA; McCord AM; Kwak LW
    J Clin Oncol; 2011 Dec; 29(36):4845-6. PubMed ID: 22042953
    [No Abstract]   [Full Text] [Related]  

  • 56. Idiotype vaccination for lymphoma: moving towards optimisation.
    Houot R; Levy R
    Leuk Lymphoma; 2009 Jan; 50(1):1-2. PubMed ID: 19172492
    [No Abstract]   [Full Text] [Related]  

  • 57. Evidence for idiotype-directed immunosurveillance is restricted to follicular lymphoma and attributable to somatic hypermutation.
    Papaioannou D; Strothmeyer AM; Dühren-von Minden M; Keppler-Hafkemeyer A; Zirlik K; Mikesch K; van Bergen CA; Navarrete MA; Veelken H
    Haematologica; 2015 Apr; 100(4):e143-6. PubMed ID: 25616573
    [No Abstract]   [Full Text] [Related]  

  • 58. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
    Bendandi M; Gocke CD; Kobrin CB; Benko FA; Sternas LA; Pennington R; Watson TM; Reynolds CW; Gause BL; Duffey PL; Jaffe ES; Creekmore SP; Longo DL; Kwak LW
    Nat Med; 1999 Oct; 5(10):1171-7. PubMed ID: 10502821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma.
    Casales E; Martisova E; Villanueva H; de Cerio ALD; Inoges S; Silva-Pilipich N; Ballesteros-Briones MC; Aranda A; Bezunartea J; Bendandi M; Pastor F; Smerdou C
    Sci Rep; 2021 Nov; 11(1):21427. PubMed ID: 34728659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells.
    Osterroth F; Garbe A; Fisch P; Veelken H
    Blood; 2000 Feb; 95(4):1342-9. PubMed ID: 10666209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.